Abbott hepatitis C drugs bring high cure rates in trial

Sun Nov 11, 2012 12:28am IST

An earthquake survivor receives a vaccination against hepatitis in Concepcion March 10, 2010. REUTERS/Jose Luis Saavedra/Files

An earthquake survivor receives a vaccination against hepatitis in Concepcion March 10, 2010.

Credit: Reuters/Jose Luis Saavedra/Files

Related Topics

Stocks

   

REUTERS - A trio of oral medicines from Abbott Laboratories Inc to treat hepatitis C produced unprecedented cure rates in patients who had failed to benefit from standard treatment, as well as very high cure rates for newly treated patients, Abbott said on Saturday.

Detailed data from the mid-stage trial, called Aviator, were released Saturday at the annual meeting of the American Association for the Study of Liver Disease (AASLD) in Boston.

Investors and patients have very high hopes for the Abbott drugs - a protease inhibitor called ABT-450, a polymerase inhibitor ABT-333 and ABT-267 from a class known as NS5A inhibitors. They are used without interferon, an injectable standard treatment that causes flu-like symptoms.

Abbott said it plans to move ahead with large Phase III studies of the three drugs, used either with or without the standard antiviral pill ribavirin, based on favorable results seen in patients treated for eight weeks or twelve weeks in the Aviator study. Patients in the study had the most common, and hardest-to-treat, strain of hepatitis C known as Genotype 1.

Some 93 percent of patients who failed prior therapy had a sustained virologic response (SVR), meaning they were considered cured, after 12 weeks of taking the trio of new drugs, plus ribavirin.

"Nobody anywhere has broken the 50 percent mark in (cure rates) for this population," Scott Brun, a senior Abbott research executive said in an interview. "These are robust results."

Abbott said it aims to be the first company to market an interferon-free regimen to patients with Genotype 1 infections.

Four of 448 patients in the study discontinued treatment due to adverse events, a dropout rate that Abbott said suggested the medicines were very well tolerated.

About 97 percent of previously untreated patients were considered cured after 12 weeks of treatment with the three Abbott drugs, plus ribavirin. Moreover, similarly impressive cure rates were seen among patients taking the three drugs, plus ribavirin, for 8 weeks.

Without ribavirin, 87 percent of previously untreated patients were considered cured after 12 weeks on Abbott's three drugs, Abbott said.

Rival drugmaker Gilead Sciences Inc (GILD.O) stole a bit of Abbott's thunder on Saturday by releasing data showing a 100 percent cure rate among previously untreated genotype 1 patients who took only two of its oral treatments, plus ribavirin, for 12 weeks.

A pair of new hepatitis C drugs approved last year, Vertex Pharmaceuticals Inc's (VRTX.O) Incivek and Merck & Co's (MRK.N) Victrelis, significantly boosted cure rates and cut treatment duration to as low as 24 weeks for some patients. But the protease inhibitors must still be taken with interferon, an injected drug that often causes severe flu-like symptoms that lead many hepatitis patients to delay or discontinue treatment.

Gilead, Bristol-Myers Squibb Co (BMY.N) and Vertex are racing to develop interferon-free treatment regimens. They are expected to become blockbuster products, if approved, because of their far shorter treatment times and better cure rates, compared with existing drug regimens.

Many analysts view Gilead as current leader both on timing and perceived advantages of its experimental hepatitis C program.

An estimated 3 million Americans are believed infected with the virus, which quietly damages the liver over years or decades and is the biggest reason for liver transplants in the United States. Abbott said as many as 170 million people worldwide are infected.

(Reporting by Ransdell Pierson; Editing by Vicki Allen and Jackie Frank)

FILED UNDER:
Photo

After wave of QE, onus shifts to leaders to boost economy

DAVOS, Switzerland - Central banks have done their best to rescue the world economy by printing money and politicians must now act fast to enact structural reforms and pro-investment policies to boost growth, central bankers said on Saturday.

Obama's India Visit

Reuters Showcase

Obama's Message

Obama's Message

In parting shot, Obama prods India on religious freedom.  Full Article 

Armyman Killed

Armyman Killed

Indian army colonel killed in Kashmir fighting.  Full Article 

Uber in Delhi

Uber in Delhi

Uber scraps commissions for its New Delhi taxis.  Full Article 

Company Earnings

Company Earnings

Maruti promises clarity on cash plans.  Full Article 

Japan Hostages

Japan Hostages

Japan vows to work with Jordan to secure hostage release.  Full Article 

RK Laxman Dead

RK Laxman Dead

'Common Man' cartoonist RK Laxman dead at 93  Full Article 

India’s Male Tenor

India’s Male Tenor

India’s lone male tenor wants to ‘Indianise’ opera  Full Article 

Facebook Outage

Facebook Outage

Hacker group claims it is behind outages at Facebook, other sites  Full Article 

U.S. Blizzard

U.S. Blizzard

`Life-threatening' blizzard shuts down much of U.S. Northeast  Full Article 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device  Full Coverage